Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Methylprednisolone · Depo-Medrol, Medrol Acetate

Small molecule · Agonist of glucocorticoid receptor (NR3C1) · developed by Pfizer

Approved FDA, Oct 1957

4 Registered trials

What is Methylprednisolone?

Methylprednisolone is a synthetic corticosteroid that binds and activates glucocorticoid receptors, altering gene expression and inhibiting proinflammatory cytokine production. It decreases circulating lymphocytes and induces apoptosis in sensitive cells.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Depo-Medrol, Medrol Acetate, Solu-Medrol, Medrol, Solu-Medrol, Depo-Medrol, Medrol, Adlone, Caberdelta M
Drug type: Small molecule
Targets: glucocorticoid receptor (NR3C1)
Mechanism: Agonist of glucocorticoid receptor (NR3C1)
Pathways: proinflammatory cytokine production inhibition, lymphocyte apoptosis
Therapy area: Hematology
Developer: Pfizer
In trials of: BLRX, BMY, GILD, RKTO
FDA status: Approved as Depo-Medrol, Medrol Acetate, Solu-Medrol (October 24, 1957), NDA011153 · FDA label

✅ FDA-approved uses

Severe or incapacitating allergic conditions (Solu-Medrol)
Bullous dermatitis herpetiformis (Solu-Medrol)
Severe erythema multiforme (Stevens-Johnson syndrome) (Solu-Medrol)
Primary or secondary adrenocortical insufficiency (Solu-Medrol)
Congenital adrenal hyperplasia (Solu-Medrol)
Hypercalcemia associated with cancer (Solu-Medrol)
Regional enteritis and ulcerative colitis (Solu-Medrol)
Rheumatoid arthritis (Methylprednisolone)

From the indications section of the FDA label (version of Jul 23, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07763210	Phase 2	Non-hodgkin Lymphoma	Recruiting	GILD
NCT02462252	Phase 2	Aplastic Anemia	Completed	BLRX
NCT01790594	Phase 2	Simultaneous Kidney and Pancreas Transplantation	Terminated	BMY
NCT01331018	Phase 1	Fanconi Anemia	Terminated	RKTO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non-hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Mantle Cell LymphomaRefractory Mantle Cell LymphomaRefractory Marginal Zone LymphomaAplastic AnemiaFanconi AnemiaHypoplastic Myelodysplastic SyndromeSimultaneous Kidney and Pancreas Transplantation

Other drugs acting on NR3C1

Beclomethasone Dipropionate FDA approved Budesonide FDA approved IDP-118 FDA approved Infacort FDA approved Mifepristone FDA approved Mometasone FDA approved Mometasone Furoate FDA approved Relacorilant FDA approved Chronocort Phase 3 Exicorilant Phase 1/2 Miricorilant Phase 2 ORIC-101 Phase 1

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z